ELN iMDS flow working group validation of the monocyte assay for chronic myelomonocytic leukemia diagnosis by flow cytometry.
chronic myelomonocytic leukemia
classical monocytes
flow cytometry
monocytes
myelodysplastic syndrome
Journal
Cytometry. Part B, Clinical cytometry
ISSN: 1552-4957
Titre abrégé: Cytometry B Clin Cytom
Pays: United States
ID NLM: 101235690
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
11
2021
received:
09
07
2021
accepted:
21
12
2021
pubmed:
31
12
2021
medline:
19
1
2023
entrez:
30
12
2021
Statut:
ppublish
Résumé
It was proposed that peripheral blood (PB) monocyte profiles evaluated by flow cytometry, called "monocyte assay," could rapidly and efficiently distinguish chronic myelomonocytic leukemia (CMML) from other causes of monocytosis by highlighting an increase in the classical monocyte (cMo) fraction above 94%. However, the robustness of this assay requires a large multicenter validation and the assessment of its feasibility on bone marrow (BM) samples, as some centers may not have access to PB. PB and/or BM samples from patients displaying monocytosis were assessed with the "monocyte assay" by 10 ELN iMDS Flow working group centers with harmonized protocols. The corresponding files were reanalyzed in a blind fashion and the cMo percentages obtained by both analyses were compared. Confirmed diagnoses were collected when available. The comparison between cMo percentages from 267 PB files showed a good global significant correlation (r = 0.88) with no bias. Confirmed diagnoses, available for 212 patients, achieved a 94% sensitivity and an 84% specificity. Hence, 95/101 CMML patients displayed cMo ≥94% while cMo <94% was observed in 83/99 patients with reactive monocytosis and in 10/12 patients with myeloproliferative neoplasms (MPN) with monocytosis. The established Receiver Operator Curve again provided a 94% cut-off value of cMo. The 117 BM files reanalysis led to an 87% sensitivity and an 80% specificity, with excellent correlation between the 43 paired samples to PB. This ELN multicenter study demonstrates the robustness of the monocyte assay with only limited variability of cMo percentages, validates the 94% cutoff value, confirms its high sensitivity and specificity in PB and finally, also confirms the possibility of its use in BM samples.
Sections du résumé
BACKGROUND
It was proposed that peripheral blood (PB) monocyte profiles evaluated by flow cytometry, called "monocyte assay," could rapidly and efficiently distinguish chronic myelomonocytic leukemia (CMML) from other causes of monocytosis by highlighting an increase in the classical monocyte (cMo) fraction above 94%. However, the robustness of this assay requires a large multicenter validation and the assessment of its feasibility on bone marrow (BM) samples, as some centers may not have access to PB.
METHODS
PB and/or BM samples from patients displaying monocytosis were assessed with the "monocyte assay" by 10 ELN iMDS Flow working group centers with harmonized protocols. The corresponding files were reanalyzed in a blind fashion and the cMo percentages obtained by both analyses were compared. Confirmed diagnoses were collected when available.
RESULTS
The comparison between cMo percentages from 267 PB files showed a good global significant correlation (r = 0.88) with no bias. Confirmed diagnoses, available for 212 patients, achieved a 94% sensitivity and an 84% specificity. Hence, 95/101 CMML patients displayed cMo ≥94% while cMo <94% was observed in 83/99 patients with reactive monocytosis and in 10/12 patients with myeloproliferative neoplasms (MPN) with monocytosis. The established Receiver Operator Curve again provided a 94% cut-off value of cMo. The 117 BM files reanalysis led to an 87% sensitivity and an 80% specificity, with excellent correlation between the 43 paired samples to PB.
CONCLUSIONS
This ELN multicenter study demonstrates the robustness of the monocyte assay with only limited variability of cMo percentages, validates the 94% cutoff value, confirms its high sensitivity and specificity in PB and finally, also confirms the possibility of its use in BM samples.
Identifiants
pubmed: 34967500
doi: 10.1002/cyto.b.22054
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
66-76Informations de copyright
© 2021 International Clinical Cytometry Society.
Références
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127, 2391-2405.
Ball, M., List, A. F., & Padron, E. (2016). When clinical heterogeneity exceeds genetic heterogeneity: Thinking outside the genomic box in chronic myelomonocytic leukemia. Blood, 128, 2381-2387.
Cargo, C., Cullen, M., Taylor, J., Short, M., Glover, P., Van Hoppe, S., Smith, A., Evans, P., & Crouch, S. (2019). The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis. Blood, 133, 1325-1334.
Greenberg, P. L. (2017). The classical nature of distinctive CMML monocytes. Blood, 129, 1745-1746.
Hofer, T. P., van de Loosdrecht, A. A., Stahl-Hennig, C., Cassatella, M. A., & Ziegler-Heitbrock, L. (2019). 6-Sulfo LacNAc (Slan) as a marker for non-classical monocytes. Frontiers in Immunology, 10, 2052.
Hudson, C. A., Burack, W. R., Leary, P. C., & Bennett, J. M. (2018). Clinical utility of classical and nonclassical monocyte percentage in the diagnosis of chronic Myelomonocytic leukemia. American Journal of Clinical Pathology, 150, 293-302.
Itzykson, R., Fenaux, P., Bowen, D., Cross, N. C. P., Cortes, J., De Witte, T., Germing, U., Onida, F., Padron, E., Platzbecker, U., Santini, V., Sanz, G. F., Solary, E., Van de Loosdrecht, A., & Malcovati, L. (2018). Diagnosis and treatment of chronic Myelomonocytic Leukemias in adults: Recommendations from the European Hematology Association and the European LeukemiaNet. Hema, 2, e150.
Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., Vey, N., Braun, T., Haferlach, T., Dreyfus, F., Cross, N. C. P., Preudhomme, C., Bernard, O. A., Fontenay, M., Vainchenker, W., … Solary, E. (2013). Prognostic score including gene mutations in chronic myelomonocytic leukemia. Journal of Clinical Oncology, 31, 2428-2436.
Itzykson, R., Kosmider, O., Renneville, A., Morabito, M., Preudhomme, C., Berthon, C., Adès, L., Fenaux, P., Platzbecker, U., Gagey, O., Rameau, P., Meurice, G., Oréar, C., Delhommeau, F., Bernard, O. A., Fontenay, M., Vainchenker, W., Droin, N., & Solary, E. (2013). Clonal architecture of chronic myelomonocytic leukemias. Blood, 121, 2186-2198.
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., Higgins, J. M., Moltchanov, V., Kuo, F. C., Kluk, M. J., Henderson, B., Kinnunen, L., Koistinen, H. A., Ladenvall, C., Getz, G., … Ebert, B. L. (2014). Age-related clonal hematopoiesis associated with adverse outcomes. The New England Journal of Medicine, 371, 2488-2498.
Jankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., Hsi, E. D., List, A., Sekeres, M. A., Rao, A., McDevitt, M. A., & Maciejewski, J. P. (2011). Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood, 118, 3932-3941.
Kon, A., Shih, L.-Y., Minamino, M., Sanada, M., Shiraishi, Y., Nagata, Y., Yoshida, K., Okuno, Y., Bando, M., Nakato, R., Ishikawa, S., Sato-Otsubo, A., Nagae, G., Nishimoto, A., Haferlach, C., Nowak, D., Sato, Y., Alpermann, T., Nagasaki, M., … Ogawa, S. (2013). Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nature Genetics, 45, 1232-1237.
Malcovati, L., Papaemmanuil, E., Ambaglio, I., Elena, C., Gallì, A., Della Porta, M. G., Travaglino, E., Pietra, D., Pascutto, C., Ubezio, M., Bono, E., da Vià, M. C., Brisci, A., Bruno, F., Cremonesi, L., Ferrari, M., Boveri, E., Invernizzi, R., Campbell, P. J., & Cazzola, M. (2014). Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood, 124, 1513-1521.
Mangaonkar, A. A., & Patnaik, M. M. (2019). Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. Advances in Cell and Gene Therapy, 2, e48.
Merlevede, J., Droin, N., Qin, T., Meldi, K., Yoshida, K., Morabito, M., Chautard, E., Auboeuf, D., Fenaux, P., Braun, T., Itzykson, R., de Botton, S., Quesnel, B., Commes, T., Jourdan, E., Vainchenker, W., Bernard, O., Pata-Merci, N., Solier, S., … Solary, E. (2016). Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 7, 10767.
Orazi, A., Bennett, J. M., Germing, U., Brunning, R. D., Bain, B. J., Cazzola, M., Foucar, K., & Thiele, J. (2017). Chronic myelomonocytic leukemia. In WHO classification of tumours of haematopoietic and lymphoid tissues (pp. 82-86). International Agency for Research on Cancer (IARC).
Patnaik, M. M., Timm, M. M., Vallapureddy, R., Lasho, T. L., Ketterling, R. P., Gangat, N., Shi, M., Tefferi, A., Solary, E., Reichard, K. K., & Jevremovic, D. (2017). Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer Journal, 7, e584.
Porwit, A., Oelschlaegel, U., Westers, T. M., Wagner-Ballon, O., Preijers, F., Béné, M. C., et al. (2022). Flow cytometry analysis in evaluation of myelodysplasia: Analytical issues. Recommendations from the international/European LeukemiaNet working Group for Flow Cytometry in MDS. Cytometry Part B - Clinical Cytometry. (under review).
Selimoglu-Buet, D., Badaoui, B., Benayoun, E., Toma, A., Fenaux, P., Quesnel, B., Etienne, G., Braun, T., Abermil, N., Morabito, M., Droin, N., Solary, E., Wagner-Ballon, O., & Groupe Francophone des Myélodysplasies. (2017). Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML. Blood, 130, 832-835.
Selimoglu-Buet, D., Wagner-Ballon, O., Saada, V., Bardet, V., Itzykson, R., Bencheikh, L., Morabito, M., Met, E., Debord, C., Benayoun, E., Nloga, A. M., Fenaux, P., Braun, T., Willekens, C., Quesnel, B., Adès, L., Fontenay, M., Rameau, P., Droin, N., … Francophone Myelodysplasia Group. (2015). Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood, 125, 3618-3626.
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015). Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 126, 9-16.
Such, E., Cervera, J., Costa, D., Solé, F., Vallespí, T., Luño, E., Collado, R., Calasanz, M. J., Hernández-Rivas, J. M., Cigudosa, J. C., Nomdedeu, B., Mallo, M., Carbonell, F., Bueno, J., Ardanaz, M. T., Ramos, F., Tormo, M., Sancho-Tello, R., del Cañizo, C., et al. (2011). Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 96, 375-383.
Talati, C., Zhang, L., Shaheen, G., Kuykendall, A., Ball, M., Zhang, Q., Lancet, J. E., Zuckerman, K. S., List, A. F., Komrokji, R., Moscinski, L., & Padron, E. (2017). Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood, 129, 1881-1883.
Tarfi, S., Badaoui, B., Freynet, N., Morabito, M., Lafosse, J., Toma, A., Etienne, G., Micol, J.-B., Sloma, I., Fenaux, P., Solary, E., Selimoglu-Buet, D., & Wagner-Ballon, O. (2019). Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with associated inflammatory state. Haematologica, 105, e147-e152.
Tarfi, S., Harrivel, V., Dumezy, F., Guy, J., Roussel, M., Mimoun, A., Fenaux, P., Chapuis, N., Solary, E., Selimoglu-Buet, D., & Wagner-Ballon, O. (2018). Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. Blood Cancer Journal, 8, 114.
Van de Loosdrecht, A. A., Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E. M. P., Alhan, C., Duetz, C., Dunlop, A., Hobo, W., Preijers, F., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M. R., et al. (2023). Clinical application of flow Cytometry in patients with idiopathic cytopenias and suspected myelodysplastic syndrome: A report of the international consortium and the European LeukemiaNet working group. Cytometry Part B: Clinical Cytometry, 104(1), 77-86. https://doi.org/10.1002/cyto.b.22044
Van der Velden, V. H. J., Preijers, F., Johansson, U., Westers, T. M., Dunlop, A., Porwit, A., Béné, M. C., Valent, P., Te Marvelde, J., Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W., Chapuis, N., et al. (2023). Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues - Recommendations from the European LeukemiaNet. Cytometry Part B: Clinical Cytometry, 104(1), 15-26. https://doi.org/10.1002/cyto.b.22046.
Westers, T. M., Saft, L., Van der Velden, V. H., Te Marvelde, J., Dunlop, A., Ireland, R., et al. (2022). A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of MDS. Cytometry Part B: Clinical Cytometry. (under review).
Wong, K. L., Tai, J. J.-Y., Wong, W.-C., Han, H., Sem, X., Yeap, W.-H., Kourilsky, P., & Wong, S.-C. (2011). Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood, 118, e16-e31.
Wong, K. L., Yeap, W. H., Tai, J. J. Y., Ong, S. M., Dang, T. M., & Wong, S. C. (2012). The three human monocyte subsets: Implications for health and disease. Immunologic Research, 53, 41-57.
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., Ozenberger, B. A., Welch, J. S., Link, D. C., Walter, M. J., Mardis, E. R., Dipersio, J. F., Chen, F., Wilson, R. K., Ley, T. J., & Ding, L. (2014). Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 20, 1472-1478.
Zahid, M. F., Barraco, D., Lasho, T. L., Finke, C., Ketterling, R. P., Gangat, N., Hanson, C. A., Tefferi, A., & Patnaik, M. M. (2017). Spectrum of autoimmune diseases and systemic inflammatory syndromes in patients with chronic myelomonocytic leukemia. Leukemia & Lymphoma, 58, 1488-1493.
Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., Dalod, M., Grau, V., Hart, D. N., Leenen, P. J. M., Liu, Y.-J., MacPherson, G., Randolph, G. J., Scherberich, J., Schmitz, J., Shortman, K., Sozzani, S., Strobl, H., Zembala, M., Austyn, J. M., & Lutz, M. B. (2010). Nomenclature of monocytes and dendritic cells in blood. Blood, 116, e74-e80.